Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical modelsStefano Pierini(Carisma Therapeutics (United States)), Michael Klichinsky(Carisma Therapeutics (United States))Nature CommunicationsJanuary 15, 202510.1038/s41467-024-55770-1Cited by 80SaveCiteExport RISWatch citationsRelated PapersCAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial|Nature Medicine|2025|189Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy|Molecular Therapy|2023|57Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target|JCI Insight|2020|27